Jeremy Levin was hired as chief executive officer of Teva Pharmaceuticals on Jan. 1, 2012 to help revive the languishing stock price and he has been trying to rally Wall Street for a bit more than a year.
He tried again Tuesday during his presentation at the J.P. Morgan Chase Healthcare Conference in San Francisco.
"This is a company with tremendous capability," said Levin, who took control on May 9.
Wednesday's Inquirer story is here.
Levin mentioned that once upon a time Teva was among the first to employ paragraph IV patent litigation. Some would argue that has helped patients get drugs for less money, but it certainly benefited thousands of lawyers. Levin said that legal innovation must be transferred to product development.
Teva is still the world leader in generic revenue, with 1 in 6 generic prescriptions being for Teva products.
But Wall Street analysts often know gobs of history. What they and their clients care about is the future, whether a new blockbuster is just around the corner and whether the stock price will rise.
Teva, Levin told them, will be the world's "most indispensable medicine company in five years."